1. Wasley A, Grytdal S, Daniels D. Surveillance for acute viral hepatitis—United States, 2007. MMWR. Surveillance Summaries. 2009;58(3):1–27. [PubMed] 2. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recommendations and Reports. 1998;47(RR-19):1–39. [PubMed] 3. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3):62S–65S. [PubMed] 4. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection. 2011;17(2):107–115. [PubMed] 5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–521. [PubMed] 7. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nature Reviews Microbiology. 2007;5(6):453–463. [PubMed] 8. De Beeck AO, Dubuisson J. Topology of hepatitis C virus envelope glycoproteins. Reviews in Medical Virology. 2003;13(4):233–241. [PubMed] 9. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(6):2451–2455. [PubMed] 10. Jubin R. Hepatitis C IRES: translating translation into a therapeutic target. Current Opinion in Molecular Therapeutics. 2001;3(3):278–287. [PubMed] 11. Dubuisson J. Hepatitis C virus proteins. World Journal of Gastroenterology. 2007;13(17):2406–2415. [PubMed] 12. Zeisel MB, Barth H, Schuster C, Baumert TF. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Frontiers in Bioscience. 2009;14(9):3274–3285. [PMC free article] [PubMed] 13. Kohaar I, Ploss A, Korol E, et al. Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. Journal of Virology. 2010;84(14):6987–6994. [PMC free article] [PubMed] 14. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends in Endocrinology and Metabolism. 2010;21(1):33–40. [PMC free article] [PubMed] 15. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clinics in Liver Disease. 2003;7(1):45–66. [PubMed] 16. Pawlotsky JM. Hepatitis C virus population dynamics during infection. Current Topics in Microbiology and Immunology. 2006;299:261–284. [PubMed] 17. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48(6):1769–1778. [PMC free article] [PubMed] 18. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjects. Journal of Infectious Diseases. 2008;198(6):800–807. [PubMed] 19. Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PloS ONE. 2010;5(6)e10952 [PMC free article] [PubMed]
20. Rodriguez C, Chevaliez S, Bensadoun P, et al. Ultra-deep pyrosequencing, a powerful new tool to study HBV resistance to nucleoside/nucleotide analogues, identifies preexisting HBV variants bearing resistance mutations and characterizes their on-treatment kinetics. Hepatology. 2010;52:441A–442A.
21. Verbinnen T, Van Marck H, Vandenbroucke I, et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. Journal of Virology. 2010;84(21):11124–11133. [PMC free article] [PubMed] 22. Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections. Handbook of Experimental Pharmacology. 2009;189:203–241. [PubMed] 23. Kim CS, Jung JH, Wakita T, Seung KY, Sung KJ. Monitoring the antiviral effect of alpha interferon on individual cells. Journal of Virology. 2007;81(16):8814–8820. [PMC free article] [PubMed] 24. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor: comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. The Journal of Biological Chemistry. 1991;266(28):18846–18853. [PubMed] 25. Lien E, Liabakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. European Journal of Immunology. 1995;25(9):2714–2717. [PubMed] 26. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 1990;2(6):402–406. [PubMed] 27. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. European Journal of Immunology. 1994;24(11):2699–2705. [PubMed] 28. Tilg H, Vogel W, Dinarello CA. Interferon-α induces circulating tumor necrosis factor receptor p55 in humans. Blood. 1995;85(2):433–435. [PubMed]
29. Neumann AU, Zeuzem S, Ferrari C, et al. DITTO-HCV early viral kinetics report: novel decline patterns in genotype 1 but not genotypes 2 and 3 patients treated with peg-interferon alfa-2a and ribavirin. Journal of Hepatology. 2002;36(supplement 1, article 121)
30. Pawlotsky JM, Hezode C, Pellegrin B, et al. Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology. 2002;36, article 291A
31. Pawlotsky JM. Treating hepatitis C in “difficult-to-treat” patients. The New England Journal of Medicine. 2004;351(5):422–423. [PubMed] 32. Lau JYN, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35(5):1002–1009. [PubMed] 33. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131(4):1040–1048. [PubMed] 34. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. Journal of Virology. 2002;76(17):8505–8517. [PMC free article] [PubMed] 35. Chevaliez S, Brillet R, Lázaro E, Hézode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. Journal of Virology. 2007;81(14):7732–7741. [PMC free article] [PubMed] 36. Lutchman G, Danehower S, Song BC, et al. Mutation rate of the hepatitis C virus NS5b in patients undergoing treatment with ribavirin mono-therapy. Gastroenterology. 2007;132(5):1757–1766. [PubMed] 37. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. Journal of Hepatology. 2000;33(5):791–798. [PubMed] 38. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology. 2007;46(5):1548–1563. [PMC free article] [PubMed] 39. Tang KH, Herrmann E, Cooksley H, et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Journal of Hepatology. 2005;43(5):776–782. [PubMed] 40. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967–972. [PubMed] 41. Ji X, Cheung R, Cooper S, et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003;37(3):610–621. [PubMed] 42. Araújo ES, Courtouké C, Barone AA. Hepatitis C treatment: shorter and better? Brazilian Journal of Infectious Diseases. 2007;11(1):118–124. [PubMed] 43. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 1998;282(5386):103–107. [PubMed] 44. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine. 2009;360(18):1839–1850. [PubMed] 45. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Science Translational Medicine. 2010;2:1–20. [PMC free article] [PubMed] 46. Clavel F, Hance AJ. HIV drug resistance. The New England Journal of Medicine. 2004;350(10):1023–1035. [PubMed] 47. Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology. 2009;2(4):205–219. [PMC free article] [PubMed] 48. Adiwijaya BS, Herrmann E, Hare B, et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Computational Biology. 2010;6(4)e1000745 [PMC free article] [PubMed] 49. He Y, King MS, Kempf DJ, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrobial Agents and Chemotherapy. 2008;52(3):1101–1110. [PMC free article] [PubMed] 50. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. The Journal of Biological Chemistry. 2005;280(44):36784–36791. [PubMed] 51. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. The Journal of Biological Chemistry. 2004;279(17):17508–17514. [PubMed] 52. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Research. 2006;70(2):28–38. [PubMed] 53. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Research. 2008;77(3):177–185. [PubMed] 54. Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biology. 2008;9(1, article R16) [PMC free article] [PubMed] 55. Zhou Y, Müh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon α The Journal of Biological Chemistry. 2007;282(31):22619–22628. [PubMed] 56. Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrobial Agents and Chemotherapy. 2008;52(1):110–120. [PMC free article] [PubMed] 57. Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(49):20986–20991. [PubMed] 58. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46(3):631–639. [PubMed] 59. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132(5):1767–1777. [PubMed]
60. Bartels DJ, DeMeyer S, Sullivan J, et al. Summary of clinical virology findings from clinical trials of telaprevir. Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 2011; San Francisco, Calif, USA. Abstract 1328.
Incivek [package insert] Vertex Pharmaceuticals Incorporated, Cambridge, Mass, USA, 2011.
63. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferonalfa-2a and ribavirin: interim analysis of the EXTEND study. Proceedings of the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD ’10); October 2010; Boston, Mass, USA. Abstract 227.
64. Sherman KE, Sulkowski MS, Zoulim F, et al. Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis from the EXTEND study. Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 2011; San Francisco, Calif, USA. Abstract 248.
65. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50(6):1709–1718. [PubMed] 66. Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrobial Agents and Chemotherapy. 2004;48(6):2260–2266. [PMC free article] [PubMed]
67. Sulkowski M, Poordad F, McCone J, et al. BOC combined with P/R for treatment-naïve patients with HCV genotype-1: SPRINT-2 final results. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI ’11); February 2011; Boston, Mass, USA.
68. Gordon S, Bacon B, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologicresponse among genotype-1 previous non-responders and relapsers to pegIFN/RBV when re-treated with BOC + PEGINTRON/RBV. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI ’11); February 2011; Boston, Mass, USA.
69. Victrelis [package insert] Merck & Company Incorporated, Whitehouse Station, NJ, USA, 2011.
71. Barnard RJ, Zeuzem S, Vierling JM, et al. Analysis of resistance-associated amino acid variants (RAVs) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase III clinical studies. Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 2011; San Francisco, Calif, USA. Abstract 164.
72. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011;53(5):1742–1751. [PubMed] 73. Baidick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47(5):1473–1482. [PubMed] 74. Pallier C, Castéra L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. Journal of Virology. 2006;80(2):643–653. [PMC free article] [PubMed] 75. Palleir C, Rodriguez C, Brillet R, Nordmann P, Hézode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology. 2009;49(1):50–59. [PMC free article] [PubMed]
76. Kwo P, Lawitz J, McCone J, et al. HCV SPRINT-1 final results: SVR 24 from a phase II study of boceprevir plus peginterferon alfa-2b/ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C. Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver; April 2009; Copenhagen, Denmark.
77. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine. 2010;362(14):1292–1303. [PubMed]
78. Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. Proceedings of the EASL 46th Annual Meeting; March 2011; Berlin, Germany.
79. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine. 2011;364(25):2405–2416. [PubMed] 80. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. [PubMed] 81. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–129. [PubMed]
82. Gane EJ, Stedman CA, Hyland RJ, et al. ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver; April 2012; Barcelona, Spain.
83. Lawitz E, Poordad F, Kowdley KV, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naïve HCV IL28B-CC genotype-1-infected subject. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver; April 2012; Barcelona, Spain. Abstract 1187.
84. Poordad F, Lawitz E, Kowdley KV, et al. 12-week interferon-free regimen of ABT-450/ritonavir + ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naïve HCV genotype-1-infected subjects and 47% of previous non-responders. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver; April 2012; Barcelona, Spain. Abstract 1399.